Repligen Corp

XNASHealth care

Last traded price · USD

$178.20

−0.04%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $183.40
Previous close: $178.27
Volume: 1.1M
Day's high: $188.50
Day's low: $174.39

In brief

Repligen Corp is a health care company listed on Nasdaq, valued at about $11.31B.
Its shares closed at $178.20 on 4 Nov 2026, up 21.3% over the past year.
From India you can buy RGEN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Repligen Corp (RGEN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole RGEN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade RGEN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Short interest at 12.7% of shares outstanding
7.1M shares were sold short at the 15 Oct 2026 settlement, 12.7% of the 56.4M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +1.9% (SPY −1.6%, XLV +13.5%). 3 months: +12.4% (SPY −0.4%, XLV +15.5%). 1 year: +21.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RGEN, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $178.20 was 0.3% above its 50-day average ($177.75) and 22.9% above its 200-day average ($144.97). It has closed above the 200-day for 71 sessions, since 28 Jul 2026. The 50-day average crossed above the 200-day on 12 Aug 2026, 59 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 3.4× its 30-session average on 30 Oct 2026
30 Oct 2026 volume of 4.5M shares was 3.4× the average of the 30 sessions before it (1.3M), as the price fell 6.2%. SPY traded 1.9× its own average that session.
Daily volume against a 30-session baseline · as of 30 Oct 2026
79% of the way up its 52-week range
Closed at $178.20 on 4 Nov 2026: 10.4% below the 52-week high of $198.87 (28 Sep 2026) and 76.5% above the low of $100.99 (14 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.9%

6 months+41.7%

1 year+21.3%

5 years−35.7%

Newswire

About

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Website

Notable moves

July 30, 2024
+16.37%
October 31, 2023
+17.86%
July 21, 2022
+15.25%

Newswire

About

Website

Notable moves

July 30, 2024
+16.37%
October 31, 2023
+17.86%
July 21, 2022
+15.25%

Repligen Corp

XNASHealth care

Last traded price · USD

$178.20

−0.04%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $183.40
Previous close: $178.27
Volume: 1.1M
Day's high: $188.50
Day's low: $174.39

In brief

Repligen Corp is a health care company listed on Nasdaq, valued at about $11.31B.
Its shares closed at $178.20 on 4 Nov 2026, up 21.3% over the past year.
From India you can buy RGEN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Repligen Corp (RGEN) shares from India?

Do I need the price of a whole RGEN share to invest?

How much can I invest in US stocks in a year?

Can I trade RGEN options or futures?

Insights

Quotes run fifteen minutes behind.

Short interest at 12.7% of shares outstanding
7.1M shares were sold short at the 15 Oct 2026 settlement, 12.7% of the 56.4M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +1.9% (SPY −1.6%, XLV +13.5%). 3 months: +12.4% (SPY −0.4%, XLV +15.5%). 1 year: +21.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RGEN, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $178.20 was 0.3% above its 50-day average ($177.75) and 22.9% above its 200-day average ($144.97). It has closed above the 200-day for 71 sessions, since 28 Jul 2026. The 50-day average crossed above the 200-day on 12 Aug 2026, 59 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 3.4× its 30-session average on 30 Oct 2026
30 Oct 2026 volume of 4.5M shares was 3.4× the average of the 30 sessions before it (1.3M), as the price fell 6.2%. SPY traded 1.9× its own average that session.
Daily volume against a 30-session baseline · as of 30 Oct 2026
79% of the way up its 52-week range
Closed at $178.20 on 4 Nov 2026: 10.4% below the 52-week high of $198.87 (28 Sep 2026) and 76.5% above the low of $100.99 (14 May 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.9%

6 months+41.7%

1 year+21.3%

5 years−35.7%

Newswire

About

Website

Notable moves

July 30, 2024
+16.37%
October 31, 2023
+17.86%
July 21, 2022
+15.25%

Newswire

About

Website

Notable moves

July 30, 2024
+16.37%
October 31, 2023
+17.86%
July 21, 2022
+15.25%

Repligen Corp

Repligen Corp in brief

Short interest at 12.7% of shares outstanding

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Volume 3.4× its 30-session average on 30 Oct 2026

79% of the way up its 52-week range

Repligen Corp

Repligen Corp in brief

Short interest at 12.7% of shares outstanding

Ahead of SPY, behind its sector fund XLV over 1 year

Above its 50- and 200-day averages

Volume 3.4× its 30-session average on 30 Oct 2026

79% of the way up its 52-week range